# Bill Ringo

> Bill Ringo is a startup investor at Eli Lilly. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Eli Lilly](https://shizune.co/investors/profile/eli-lilly)
- Last updated: Aug 2026

Bill Ringo is a senior advisor for Barclays Capital and executive in residence at Sofinnova Ventures. He is also Chairman of the Board for Sangamo Biosciences and a board member for Marcadia Biotech. Prior to that, he was Senior Vice President of Strategy and Business Development at Pfizer, with responsibility for guiding the company’s overallstrategic planning and business development activities.Prior to joining Pfizer in 2008, Mr. Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From 2004 to 2006, he was President and CEO of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which purchased Abgenix in 2006.From 2001 to 2004, he served on various boards - including the board of Encysive Pharmaceuticals, and was associated with Intermune, where he was appointed interim chief executive officer to help restructure the company and recruit new operational leadership.Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure there he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit, and Vice President of Sales and Marketing for U.S. Pharmaceuticals.

## About Eli Lilly

VC Fund · Indianapolis, United States

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.

5 contacts available at Eli Lilly.

| Name | Title | Profile |
| --- | --- | --- |
| Barton Peterson | Senior Vice President, Corporate Affairs & Communications | https://shizune.co/investors/profile/barton-r-peterson |
| Bill Ringo | President | https://shizune.co/investors/profile/bill-ringo |
| Daniel Skovronsky | Senior Vice President, and Chief Scientific Officer | https://shizune.co/investors/profile/daniel-m-skovronsky |
| Dr Eddie Guzdar | Senior Medical Director - Immunology Northern Europe | https://shizune.co/investors/profile/dr-eddie-guzdar |
| Eric Dozier | SVP, Human Resources, and Diversity | https://shizune.co/investors/profile/eric-dozier-06d4 |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co